Bookmark and Share

Compound Summary for: CID 11281011

arbaclofen placarbil

Also known as: XP 19986; XP-19986; 847353-30-4; SureCN351833; UNII-W89H91R7VX; CHEMBL2107312; Arbaclofen placarbil (USAN/INN)
Molecular Formula: C19H26ClNO6   Molecular Weight: 399.86584   InChIKey: JXTAALBWJQJLGN-KSSFIOAISA-N
Arbaclofen Placerbil is a prodrug of Arbaclofen, which is a selective gamma-amino-butyric acid type B receptor agonist and the R-enantiomer of baclofen. It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties. Arbaclofen Placerbil was believed to have therapeutic potential in treating gastroesophogeal reflux disease (GERD) and plasticity; however due to discouraging clinical trial results, the drug was abandoned by XenoPort in 2011 for the treatment of GERD. On May 20th, 2013, XenoPort announced plans to terminate the development of Arbaclofen Placerbil for the treatment of multiple sclerosis.    From: DrugBank
Show subcontent titlesTable of Contents
Identification
Related Records
show all 3 sub-sections (Related Compounds with Annotation, Related Compounds, Related Substances)
Use and Manufacturing
Pharmacology
Literature
Patents
Biomolecular Interactions and Pathways
Classification
Chemical and Physical Properties
_ _